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Since the first clinical orthotopic liver transplant was per-
formed 13 years ago, approximately 175 patients have under-
gone this procedure. The Denver series constitutes about 40% 
of this total experience. In our series, the overall I-year sur-
vival has been 19%; the longest survivor is now 6¥J years post-
transplantation. Most of the early deaths have been caused by 
technical complications, frequently related to difficulties in 
establishing and maintaining adequate biliary drainage. The 
late deaths have been from a variety of causes, including re-
current tumor, hepatitis, bile duct obstruction, and chronic 
rejection. 
Favorable indications for liver transplantation include 
biliary atresia, chronic aggressive hepatitis, inborn errors of 
metabolism, and certain other benign hepatic diseases. Alco-
holic cirrhosis is a less favorable indication and primary he-
patic malignancy is a relative contraindication. The immuno-
logic criteria for donor-recipient selection are much less rigid 
than for renal transplantation. 
Biliary reconstruction is the principal technical problem 
encountered with orthotopic liver transplantation. Guidelines 
for the establishment of biliary drainage, its evaluation, and 
the management of postoperative biliary complications are 
discussed. 
The first orthotopic liver transplant in man was 
performed on March I, 1963 at the University of Col-
orado [I]. Since then. approximately 275 patients 
have been treated with this procedure throughout the 
world. The Denver series now includes 114 patients 
or about 40% of the total experience. The second 
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most active group in the field has been composed of 
personnel at Addenbrooke's Hospital, Cambridge. 
and at King's College Hospital, London. The British 
inter-university effort has involved the fruitful collabo-
ration of the surgeon. Professor Roy CaIne. and the 
gastroenterologist. Professor Roger Williams, and 
has resulted in approximately 50 orthotopic liver 
transplantations. The numerous and important con-
tributions [2-4] from the United Kingdom group 
should be perused by anyone deeply interested in this 
subject. 
Six months ago. we described in detail the results in 
our first 93 cases [5]. In this article, we will discuss 
our present views regarding liver transpla·,tation 
based largely on the conclusions of that report, em-
phasizing our results with the procedure, the question 
of candidacy for liver transplantation. and certain 
technical problems that have been encountered. par-
ticularly the problem of biliary reconstruction. 
Results of Lher Transplantation: University of Colo-
rado Series 
Of the 114 patients in the University of Colorado 
series. 103 were transplanted a year or more ago. 
Thirty of them. or 29%. have survived for at least I 
year after liver replacement (Table I). In recent years, 
the I-year survival figures have been generally some-
what better, fluctuating in the 25 to 45% range. 
If this heavy early mortality were to continue after 
the first year. there would be significant cause to 
question the validity of the procedure. Fortunately, 
most of the patients who reach the I-year mark con-
tinue to do well thereafter. For example. half of all 
our I-year survivors are still alive. A total of 15 
patients have reached the 2-year mark. 8 have 
reached 3 years. and 4 are 5-year survivors (Table I). 
The longest survivor in our series (and in the world) 
\ 
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Table I. Survival after liver transplantation at the University of Colorado 
Lived 
No. I year 2 years 3 years 
1963-1966 6 0 0 0 
1967 6 I 0 0 
1968 12 5 2 I 
1969 6 2 I I 
1970 10 2 I I 
1971 \I 2 2 2 
1972 II 5 3 2 
1973 13 3 3 I 
1974 20 8 3 0 
1975 8 2 0 0 
103 30 15 8 
Only patients at risk for I year are included. 
* Died after 5 11/12 years . 
• Alive 6 2/3 years. 
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is now 62f.J years post-transplantation. She is living at 
home, attending school. and has normal liver func-
tion. Two other 5-year survivors are also entirely 
well, but the fourth one died a few days short of the 6-
year mark of chronic rejection and partial biliary ob-
struction. 
The causes of death after I year are given in Table 
2. In retrospect. at least some of these late deaths 
might have been avoided, either by better patient se-
lection (in the case of recurrent tumor) or by im-
proved management, particularly of biliary tract 
problems. 
Selection of Candidates for Liver Transplantation 
Influence of Age 
Not surprisingly, younger patients have had a bet-
ter prognosis after liver transplantation than older 
ones; for patients over 40 years of age. the I-year sur-
vival has been less than 10%. The much increased 
mortality in the older recipients has largely been the 
consequence of pulmonary or other infectious com-
plications. problems with maintaining adequate nu-
trition, or neurologic complications. We believe that 
candidacy for this formidable undertaking generally 
should be limited to those under 45 years of age, and 
Table 2. Present status of 30 one-year survivors of liver 
transplantation 
Alive 15/30 
Dead 15/30 
12 months to 80 months 
12 months to 71 months 
Recurrent cancer-4 
Chronic rejection-5 
Chronic hepatitis-2 
Bile duct 
obstruction-2 
Other infections-2 
Alive 
5 years now 
0 0 
0 0 
0 0 
1* 0 
I I 
2 2 
0 2 
0 2 
0 6 
0 2 
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that potential recipients toward the upper end of this 
spectrum should be carefully evaluated pre-
operatively. 
Influence of the Original Hepatic Disease 
Prim(lry Hepatic Malignancies. A number of the early 
recipients of liver homografts were transplanted for 
non resectable hepatic malignancies. such as hepa-
toma, cholangiocarcinoma, or hemangioendothelial 
sarcoma. Of our 12 patients in this category. 7 died 
soon after transplantation of complications not re-
lated to their malignancy. The other 5 patients, how-
ever, all developed tumor recurrence and died from 
87 to 432 days after transplantation. Widespread me-
tastases were found at autopsy, and, interestingly, the 
homograft livers almost always contained tumor. 
Because of this proclivity to develop tumor recur-
rence after transplantation. we view patients with 
large, non resectable primary hepatic malignancies as 
highly questionable candidates for liver replacement. 
Exceptions to this policy have been made if a tumor is 
an incidental finding in a liver afflicted with another 
disease. For example. one of our recipients with 
biliary atresia also had a small hepatoma in the ex-
cised specimen. Not only ~as she had no evidence of 
tumor recurrence. but she is our longest survivor af-
ter liver transplantation. 
Initially we thought the so-called Klatskin tumors 
[6]. duct cell carcinomas arising at the bifurcation of 
the hepatic ducts, might be an exceptionally good in-
dication for liver transplantation. These tumors. be-
cause of their strategic location, usually become 
symptomatic while still quite small and usually kill by 
obstruction rather than by widespread disease. Four 
~atients with this malignancy have been treated by 
Itver replacement. Two died early after operation. 
The other 2 patients survived 2 years postoperatively: 
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Fig. I. The course of a child who had a failed Kasai operation but who ultimately was effectively treated with liver 
replacement. (From ref. 7 with permis~ionKF 
I died at that time of recurrent tumor in. his trans-
planted liver, and the other is alive and clinically free 
of recurrent malignancy. Although the long-term 
prognosis in such cases is still in doubt. further trials 
in younger patients are certainly warranted. 
Biliary A tresia. Children with biliary atresia are gen-
erally good candidates for liver transplantation. 
These patients usually enjoy relatively good health 
until late in the course of the disease and their livers 
often retain adequate synthetic function. In individ-
ual cases. however. it may prove difficult or even im-
possible to revascularize the homgoraft livers. either 
because of congenital anomalies of the hepatic blood 
supply. which are not uncommon in patients with 
biliary atresia, or because of technical problems 
posed by the small size of the vessels. The latter diffi-
culties have largely been overcome by employing mi-
ctosurgical techniques in reconstructing the hepatic 
blood supply. 
Several of our patients transplanted for biliary at-
resia have had prior K asai porticoenterostomy pro-
cedures. The previous operative intervention has not 
precluded successful transplantation [71. and in sev-
eral cases the Kasai procedure has successfully 
"bought time" for the patient. thus lengthening the 
period of potential candidacy for transplantation 
(Figure I ). This is obviously of particular importance 
in these youngsters for whom potential donors are 
few and far between. 
Alcoholic Cirrhosis. The results of transplantation for 
alcoholic cirrhosis have been much less satisfactory. 
Of II such patients transplanted so far. only I. a for-
mer professional football player. has achieved long-
term survival. Another patient is alive less than 2 
months after the procedure. If the patient has repu-
diated the use of alcohol. there should be no intrinsic 
contraindication to his candidacy. In practice. the un-
certain course of this disease has frequently resulted 
in procrastination in referring patients for the pro-
cedure. By the time of referral. one or more complica-
tions has usually supervened. Most commonly. 
gastrointestinal bleeding. pneumonitis or other in-
fectious complications. or hepatic encephalopathy are 
present. thereby severely jeopardizing the chances for 
recovery. Improvement in the results after trans-
plantation in this group of candidates will require 
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that these patients he referred for transplantation be-
fore these complications arise. 
. Chrollic Aggressive Hepatitis. Post necrotic cirrhosis 
or chronic aggressive hepatitis are favorable in-
dications for transplantation. Patients with these dis-
eases are usually younger than those with alcoholic 
cirrhosis and the downhill course of their disease is 
generally more predictable. If the hepatitis B antigen 
is not present preoperatively, the recipient does not 
seem to be at significant risk of developing recurrent 
hepatitis postoperatively. When antigenemia pre-
dates transplantation, antigen-positive hepatitis post-
operatively may prove to be a major threat. Indeed. 
one of our patients who was transplanted for this in-
dication developed acute antigen-positive hepatitis 
postoperatively. which progressed to chronic aggres-
sive hepatitis from which she eventually died [8]. Ret-
rospective analysis of serum samples during the early 
postoperative period showed that trace amounts of 
the antigen were still present and probably caused in-
fection of the homograft liver. Two patients with an-
tigen-positive hepatitis treated subsequently have re-
ceived high-titer anti-HB. Ag antiserum intra- and 
postoperatively. This therapy appeared to be success-
ful in eliminating the residual serum antigen remain-
ing after removal of the infected liver. Unfortunately. 
both patients died early after operation, 3 and 7 
weeks post-operatively. before clinical hepatitis could 
be expected to appear. Thus. the effectiveness of an-
tiserum therapy in preventing the subsequent occur-
rence of hepatitis will be determined only by further 
trials. 
Inborn Errors of Metabolism. Our best results with 
liver transplantation have been in patients with -he-
patic-based inborn errors of metabolism. We have 
treated 3 such diseases: Wilson's disease, alphal-an-
tilrypsin deficiency, and tyrosinemia. I n addition, 
Daloze, Corman and their associates in Montreal [9] 
have successfully transplanted a patient with Nie-
mann-Pick disease. 
I n Wilson's disease, there is progressive accumula-
tion of copper in the body. The characteristic Kayser-
Fleischer rings are an external manifestation of this, 
representing discoloration of the corneas by the metal 
deposits. More importantly. deposition of copper in 
the liver and brain may cause subsequent degenera-
tive changes. We have treated 2 children for this dis-
order [10, II]. Both survived for 5 years after trans-
plantation; one is alive and entirely well, but the 
other died of chronic rejection and partial biliary ob-
struction unrelieved by late reoperation. Metabolic 
studies in these patients showed that the copper-con-
taining cerUloplasmin, which was low or virtually ab-
sent preoperatively. became normal postoperatively. 
There was a prolonged cupriuresis postoperatively, 
which reduced the tremendously elevated total body 
World J. Sur!!. Yol. I. ~oK 2, \larch 1977 
copper content. Neither of the homografts showed 
any tendency to reaccumulate the metal. One of the 
patients had severe neurologic impairment pre-
operatively which gradually improved after trans-
plantation. becoming normal over the next 3 years .. 
Alphal-antitrypsin deficiency is a hereditary dis-
ease which predisposes to congenital infantile cir-
rhosis [12] and occasionally adult cirrhosis, as well as 
pulmonary emphysema of early onset in adults. The 
homozygous Pilz phenotype is not terribly rare; its 
incidence is estimated to be about I in 2,500 live 
births. Approximately 20 to 30% of children who 
have this phenotype will develop cirrhosis [12]. 
In November, 1973, we transplanted a 16-year-old 
girl with cirrhosis caused by alphal-antitrypsin defi-
ciency. PizZ phenotype [13]. Postoperatively. she de-
veloped normal levels of alphal-antitrypsin which 
had the donor phenotype. PiMM (Table 3). Two years 
after transplantation her graft failed from chronic re-
jection. A second transplantation was performed, the 
donor for which by coincidence had the heterozygous 
PiMZ phenotype and a correspondingly reduced serum 
alphal-antitrypsin . concentration (heterozygotes, 
however. have no predilection to develop liver dis-
ease). Following retransplantation the recipient again 
adopted the donor's phenotype, this time PiMZ (Table 
3). Unfortunately, the patient died a month later of 
pulmonary infection. but the validity of the metabolic 
correction by liver transplantation was established. 
Daloze, Corman. and their associates [9] have 
treated a 2-year-old child with Niemann-Pick disease. 
In this disorder. deposits of sphingomyelin within the 
liver cause hepatic failure. After transplantation. the 
- homograft liver showed no tendency to reaccumulate 
sphingomyelin. and sphingomyelinase, the deficient 
enzyme, could be found in normal concentrations in 
the blood, urine, cerebrospinal fluid, and the graft it-
self. Unfortunately, there was severe neurologic im-
pairment preoperatively which did not improve after 
transplantation and the child died of respiratory 
complications 2 years later. 
The fourth inborn error of metabolism which has 
been treated by liver transplantation is tyrosinemia. 
Two months ago we transpl4nted a 10-year-old child 
with this disorder who also had a multi focal hepa-
toma within her severely cirrhotic liver. Post-
operatively, the serum and urine tyrosine con-
centrations rapidly became normal and the urinary 
excretion of p-hydroxyphenyl pyruvic acid products 
gradually declined. These findings suggest that this 
disorder was corrected by transplantation; further 
metabolic studies are now in progress. 
Other Benign Hepatic Diseases. Prolonged survival 
has been achieved after liver replacement in patients 
with primary biliary cirrhosis and the Budd-Chiari 
syndrome [14]. However. we have not yet successfully 
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Table 3. Serum alphat-antitrypsin concentration and phenotypes before and after liver transplantation 
Phenotype 
Enzyme Concentration (mg%) 
(normal 140-470) 
Pretransplant 
ZZ 
55 
First 
donor 
MM 
treated patients with acute liver failure from fulmi-
nant hepatitis or other toxic agents, largely because 
of the logistic problems in obtaining an appropriate 
cadaveric organ during the brief time span in which 
such patients are satisfactory candidates for trans-
plantation. 
Criteria for Donor-Recipient Selection 
Since no artificial support system comparable to 
hemodialysis is available to potential recipients of 
liver transplants, their period of candidacy is neces-
sarily much shorter than that of patients with end-
stage renal disease. Therefore, a relaxation of criteria 
for donor-recipient selection is necessary if they are 
to be treated at all. Indeed, if the pace of deteriora-
tion of the recipient warrants doing so, all ordinary 
immunologic restrictions may be ignored and an 
A BO-incompatible or crossmatch-positive organ in-
serted. Under less pressing circumstances, of course, 
the guidelines described below are observed. 
ABO Compatibility. The rules for ABO matching of 
donor to recipient are identical to those used for 
transplantation of other organs, such as the kidney. If 
these barriers are violated in renal transplantation, 
hyperacute rejection of the organ is the" usual al-
though not invariable consequence. This does not ap-
pear to be the case after liver transplantation, since 7 
of our patients have received such ABO-incompatible 
organs without any evidence of hyperacute rejection. 
However, it is not yet clear whether these organs may 
be more susceptible to late rejection than ABO-com-
patible ones. 
Cytotoxic Antibody Crossmatch. Hyperacute rejec-
tion of renal homografts is also an extremely com-
mon occurrence if the recipient possesses preformed 
cytotoxic antibodies against donor cells. Again, the 
liver is quite resistant to this immunologic complica-
tion: the fate of hepatic homografts placed in such an 
immunologically hostile environment does not seem 
to be any different than in crossmatch-negative cases. 
HL-A Typing. Although HL-A typing is routinely 
performed, the results are not used to guide the selec-
tion of donor-recipient pairs. As a consequence of 
this policy. most of the HL-A matches have been 
poor ones (Table 4). With such a skewed spectrum of 
histocompatibility. conclusions about the predictive 
Post-transplant 
Second After 
18 months 27 months donor retransplant 
MM MM MZ MZ 
264 256 176 270 
validity of the technique cannot be drawn. Clearly. 
there is no definable correlation between the quality 
of match and survival in this limited series (Table 4). 
Techniques of Orthotopic Liver Transplantation 
The vascular reconstruction of the orthotopic liver 
homograft has largely become standardized. The 
graft vena cava is anastomosed to the analogous host 
vessels above and below the liver. The portal vein of 
• # . 
the graft IS anastomosed end-to-end to the host portal 
vein. and the hepatic artery is usually revascularized 
with the common hepatic artery of the recipient (Fig-
ure 2). 
Most of the technical problems with this procedure 
have arisen from failure to maintain satisfactory 
biliary drainage. Until 1973. biliary reconstruction 
was usually with cholecystoduodenostomy (Figure 
2A). The weak link of this technique is the cystic 
duct. which becomes obstructed in about one-third of 
the cases in which the gallbladder is used for anasto-
mosis. In the first few cases in which this occurred. 
the correct diagnosis was not made until autopsy. 
Subsequently, several cases were diagnosed during 
life by operative cholangiography, but reoperation 
was still usually too late. In 1973, a policy of per-
Table 4. HL-A typing of primary hepatic grafts in 103 cases 
Survival 
Match* No. I year 
A I It 
B 3 1 (33%) 
C 15 3 (20%) 
D 27 5 (19%) 
E 44 16(36%) 
F 6 1 (17%) 
Not done 7 1 (14%) 
--
Total 103 28 (29%) 
* A match. HL-A identity between recipient and donor: 
B match. compatibility between donor and recipient, but 
fewer antigens determined in the donor: C match. one 
antigen incompatible: D match. two antigens incompatible: 
E match. three or four antigens incompatible; F match. 
A BO violation or positive crossmatch to cytotoxic anti-
bodies. 
• Retmnsplanted after 68 days with C-match graft. Thus. 
the I -year survival was due mainly to the second. less well 
matched organ. 
----------------_. 
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T-Iube in recipient 
common duel 
forming transhepatic cholangiography whenever re-
current jaundice appeared was adopted. For this 
study, the very thin needle developed in C!1iba, g~ 
pan, was used. This technique proved to be quite safe 
and immensely helpful. 
At about the same time, an appreciation of the role 
of hepatic sepsis in these cases led to the adoption of 
Roux-en-y biliary drainage to avoid gastrointestinal 
contamination of the biliary system. The strategy that 
evolved w~s to perform cholecysto-Roux-en-y-jeju-
nostomy (Figure 28) as the primary reconstruction. 
If jaundice reappeared and transhepatic cholangio-
graphy confirmed cystic duct obstruction, the gall-
bladder was removed and a choledochojejunostomy 
created (Figure 2C). Altern~tive techniques which 
share the advantage of placing the biliary system out 
of the direct continuity with the gastroin~estinal tract 
include choledochocholedochostomy with T -tube 
drainage (Figure 20) and primary choledochojejun-
ostomy. 
It is apparent that no one technique of biliary re-
construction will be satisfactory for all patients; each 
case must be individualized. Certain principles of re-
construction, however, have emerged. Ideally, the 
biliary reconstruction should avoid using the cystic 
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Fig. 2 A-D. Techniques of biliary duct 
reconstruction used for most of the 
transplantation recipients. A. Cho-
lecystoduodenostomy. B. Cholecysto-
jejunostomy. C. Choledocllojejunos-
tomy after removal of gallbladder. D. 
Choledochocholedochostomy. Note 
that the T-tube is placed. if possible. in 
recipient common duct. (From ref. 5 
with permission.) 
duct with its inherently high risk of obstruction. Sec-
ondly. the liver should be protected from the bacte-
rially contaminated gastrointestinal contents either 
with a defunctionalized Roux-en-y limb of jejunum 
or by the sphincter of Oddi. Thirdly, radiographic 
visualization of the biliary tree, either by tube cho-
langiography or by the transhepatic approach. must 
be obtained whenever jaundice reappears after trans-
plantation. Finally, if obstruction is detected, prompt 
reoperation is vital. 
Future Prospects 
The procedure of orthotopic liver transplantation 
is a formidable one, particularly when the patient has 
significant portal hypertension and a major coagu-
lopathy. Moreover. problems with biliary reconstruc-
tion have plagued this venture during its infancy and. 
indeed. continue to do so. The necessary pre-
occupation with the technical requirements of liver 
replacement has obscured the fact that rejection has 
been much less of a problem [5] than after cadaveric 
renal homotransplantation. Yet only by the precise 
management of technical details will the benefits af-
forded by this immunologic advantage be accrued. 
Despite this advantage. liver homografts will still be 
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lost from rejection. Rather than pursuing aggressive 
immunosuppression in an attempt to prolong graft 
survival. investigators may have to show a greater 
willingness to accept the need for retransplantation, 
despite the obvious technical obstacles. 
Resume 
La premiere transplantation orthotopique du foie 
chez l'homme a ete faite il y a 13 ans. Depuis, environ 
275 patients ont benificie de cette operation et 40% 
d'entre eux ont ete operes a Denver. Dans notre serie, 
30% des patients ont surve~Du au moins I an. La plus 
longue survie est actuellement 6 ans 213. Les pro-
blemes techniques ont ete responsables de la plupart 
des deces a court terme. Quant aux deces tardifs, ils 
ont ete causes par une variete de complications in-
cluant la recidive de tumeur. I'hepatite, l'obstruction 
des voies biliaires et les phenomenes de rejet chro-
nique. Les pathologies ben ignes du foie. en particu-
lier I'atresie des voies biliaires. I'hepatite chronique 
active et les erreurs innees du metabolisme constitu-
ent les indications les plus favorables. La cirrhose al-
coolique a ete associee a des resultats moins encour-
ageants tandis que les tumeurs maligne primitives du 
roie constituent une contre-indication relative. Les 
criteres immunologiques pour la selection des don-
neurs sont moins rigides que pour la transplantation 
renale. Le principal probleme technique rencontre 
lors des transplantations orthotopiques du foie a ete 
celui de la reconstruction des voie biliaires. ie~ au-
teurs joignent a ce rapport une discussion detaillee 
portant sur ce sujet. 
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INVITED COMMENTARY 
RoY Y. CALNE, F.R.S. 
Department of Surgery, A ddenbrooke's Hospital 
Cambridge, England 
The work on liver grafting by the Denver group 
headed by Dr. Starzl has been outstanding. The re-
view of this subject by Putnam et a!. in this issue, 
based chiefly on the 114 patients treated in Denver 
since 1963, will be of great value to all interested in 
organ grafting. With a follow-up of more than a year 
for 103 of their cases and a 29% one year survival, the 
authors raise the central question on the validity of 
liver replacement as therapy. They point out that 
patients surviving a year usually continue to do well, 
50% of their one year survivors being alive at present, 
with the longest surviving patient having normal liver 
function and living a full life 6.4 years after oper-
ation. I will comment on the main points raised in 
! 
Fig. I. Diagram of pedicle graft conduit with the donor gall 
bladder. Hartmann's pouch is anastomosed to the donor 
common duct and the fundus anastomosed to the recipient 
common duct. A n irrigating T-tube is inserted with the irri-
gating arm through the upper anastomosis. Blood supply to 
the gall bladder is carefully preserved. (By courtesy of the 
British Medical Journal). 
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their article from the standpoint of an experience of 
57 orthotopic liver allografts performed in the Cam-
bridge/King's College Hospital series [1]. 
Indications 
I am sure that the Denver group are correct in aim-
ing at liver grafting in young patients, but I would not 
set an absolute upper age limit, but rather consider 
the patient's "biological" age. Moreover, although 
excellent results have been obtained in infants and 
very young children. I am reluctant to inflict this for-
midable procedure-not just the operation, but also 
the intensive pre- and postoperative surveillance and 
treatment-on a child who cannot understand the 
necessarily guarded prognosis that can at present be 
offered. 
I would agree that recurrence of primary malig-
nancies can be expected in about 75% of cases, but 
some patients are cured and many are palliated as 
well as can be achieved by comparable treatment of 
many malignant growths treated by conventional sur-
gery. My feelings concur with those of the authors on 
the other indications for liver grafting and we have 
additional data on Australia antigenemia. One of our 
patients with a primary hepatoma and antigenemia, 
treated with high titer antiserum following hepa-
tectomy, has remained antigen negative more than 6 
months after grafting. 
Donor Selection 
Although we have not transgressed ABO in-
compatibility in our cases, we have transplanted a 
liver in the face of a donor specific, strongly positive 
cross-match without untoward effect. We have also 
found the liver to be much less susceptible to rejec-
tion than the kidney, and in the past it is likely that 
many of our patients have died from the side effects 
of excessive immunosuppressive treatment. Unlike 
the Denver group we have never used antilymphocyte 
globulin, yet the incidence of uncontrollable rejection 
in our series has been comparable to the Denver 
cases, i.e. under 10%. 
Technical Considerations 
We have followed the principles laid down by the 
Denver group, but in view of the extreme shortage of 
donor organs, we have extended our donor catch-
ment area by use of simple flush cooling of the liver 
and storage in ice. Sixteen livers taken from donors in 
institutions up to 400 miles away have all functioned 
well immediately following revascularization, despite 
the period of cold ischemia having been extended to 
more than 8 hours [2). 
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Fig. 2. Diagram of the use of the vas-
cularized gall bladder as a conduit be-
tween the donor common duct and a 
long Roux loop of jejunum in a patient 
whose own common duct could not be 
used. Harfmann's pouch is anastomosed 
to the common bile duct of the donor 
and the fundus of the gall bladder to the 
Roux loop. (By courtesy of the British 
Medical Journal). 
Biliary Drainage 
, We were also plagued by an unacceptably high in-
cidence of fatal complications of biliary drainage oc-
curring in more than 50 of our cases. Many varieties 
of technique were used but one or more of the weak 
points mentioned by Putnam et al. were unavoidable 
with all conventional procedures. In the last 18 
months I have been using a new technique involving 
the vascularized gall bladder as a conduit between 
donor and recipient common duct (4] (Fig. 1). The 
anastomoses are splinted with a special T tube with 
an irrigating arm threaded through the proximal 
anastomosis. through which heparinized saline solu-
tion is infused in the early postoperative period to 
prevent biliary sludge accumulating. This form of bile 
drainage has been used in 17 cases as a primary pro-
cedure and 2 as a secondary operation following 
breakdown of duct-to-duct anastomoses. The sphinc-
ter of Oddi is preserved. wide anastomoses with good 
blood supplies are possible. there is no bile duct sump 
for accumulation of sludge and there is ready access 
to the biliary ducts for radiography. Although the 
follow-up period is short. in each patient biliary 
drainage has been initially satisfactory and the in-
cidences of biliary leakage and anastomotic stenosis 
have been markedly reduced. In one patient in whom 
the recipient common duct could not be used. the 
technique was modified by anastomosing the fundus 
of the gall bladder conduit to a long Roux loop (Fig. 
2 ). 
We agree with Putnam et al. on the validity of liver 
grafting as a form of therapy. Our experience of the 
excellent quality of life in patients with liver allografts 
discharged from hospital encourages us to continue. 
One of our patients survived 5.4 years. dying sud-
denly of cholangitis following blockage of bile drain-
1··.·1: \ 
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age. At autopsy there was no evidence of recurrent 
hepatoma. her original disease. nor were there signs 
of rejection. Currently 12 of our patients are alive. the 
longest a fler 3 years. 
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The contributions of Dr. Starzl and his colleagues 
to organ transplantation in general. and liver trans-
plantation in particular. are monumental. This report 
is particularly encouraging in that about one-third of -
patients receiving an orthotopic liver transplant are 
reported to have lived for at least a year with 
markedly improved prospects for long-term survival 
thereafter. This survival rate has been achieved while 
exploring the feasibility of liver transplantation in 
patients who were terminally ill from a variety of dis-
eases. Indeed. a great proportion would have been 
unlikely to survive even a minor operative procedure. 
With this experience. the authors are now able to bet-
ter define the place of liver transplantation. Improved 
results are expected from better patient selection. 
more knowledgeable immune suppression. accept-
ance of the concept of retransplantation if graft re-
jection or other complications so indicate. and im-
proved biliary-enteric connections. 
The authors are justifiably concerned about total 
hepatectomy and orthotopic liver transplantation for 
the patient with primary liver cancer. Their experi-
ence here is limited to the individuals who survived 
transplantation; all developed recurrent cancer. 
These 5 appear to be patients who had extensive liver 
cancers which may have already spread before liver 
transplantation. Microscopic foci in regional lymph 
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nodes or peritoneal seeding can be overlooked. Mas-
sive cancers in the liver are confined by the thin cov-
ering of Glisson's capsule. A biopsy or inadvertent 
tear of the capsule could contaminate the peritoneal 
cavity with tumor cells. Hepatocellular carcinomas 
often have tumor thrombi so that manipulations of 
the liver during its removal could dislodge these. 
leading to pulmonary metastases. It is important to 
realize that tumor recurrence in such cases is not nec-
essarily due to immune suppression which must ac-
company organ transplantation. A low cure rate can 
be expected for extensive cancers treated by any 
method including transplantation. Better selection of 
patients will undoubtedly result in cures of individ-
uals who have primary liver cancers. 
The liver involved by cholangiocarcinoma lends it-
self much more readily to liver transplantation. Tu-
mor thrombi occur less frequently than with hepato-
cellular carcinomas. The tumors tend to be less bulky 
and are commonly surrounded by a margin of nor-
mal liver ,tissue. Total hepatectomy and orthotopic 
liver transplantation appears to be an excellent way 
to treat cholangiocarcinomas involving both lobes of 
the liver. 
The biliary-enteric anastomosis has been the Ach-
illes heel of liver transplantation. We have advocated 
and practiced a Roux-en-Y end-to-side choldocho-
jejunostomy for the past 4 years. The anastomosis is 
carried out using interrupted 4-0 sutures after fish-
mouthing the end of the normal sized common bile 
duct. A stent is not used. This approach presents no 
more technical difficulties than an arterial anasto-
mosis. A small catheter or a tiny T-tube may be 
placed in the common hepatic duct for monitoring 
the contents of the bile and for carrying out cho-
langiograms in the event of development of jaundice. 
This procedure was first carried out in our liver trans-
plants on 12/13/72 after demonstration in our pre-
vious patients that a cholecystenterostomy led to an 
unacceptable frequency of complications. 
It is important to consider a heterotopic or aux-
iliary liver transplant as an alternative to the ortho-
topic transplant for patients with end-stage. non-can-
cerous liver disease. It is interesting that the risks of 
the orthotopic transplant are almost prohibitive after 
age 40. The substantially lessened operative risks. 
stress and time of the heterotopic liver transplant are 
borne out by the fact that the first successful hetero-
topic transplant was performed in a 72-year-old 
woman. She lived for 8 months after the graft with a 
transplant which functioned excellently. The con-
cluding statement in the paper of the need for a 
greater willingness to accept the concept of retrans-
plantation for severely damaged liver grafts is partic-
ularly appropriate for the auxiliary liver. A malfunc-
tioning auxiliary liver can be removed and the 
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patient's diseased liver can function as a temporary 
support until a suitable donor is obtained. We have 
recently reported on 7 heterotopic liver transplants: 3 
recipients had congenital biliary atresia, one had 
idiopathic cholestasis syndrome, 2 patients had post-
necrotic liver cirrhosis, and one patient had an in-
tractable pruritis and jaundice secondary to localized 
and unresectable bile duct cancer. One patient is liv-
ing and well 4 years after transplantation. One indi-
vidual lived 8 months with a normally functioning 
graft and succumbed to infection in her own liver sec-
ondary to obstruction by the bile duct cancer. A third 
patient initially had an uneventful course when a re-
jection reaction developed. Minimal increase in im-
munosuppression led to pneuymocystis carinii in-
fection and death at 3 V2 months. The liver had recov-
ered from the rejection and was functioning quite 
well. These results provide a sound basis for consid-
ering the heterotopic (auxiliary) transplant as an al-
ternative to the orthotopic transplant for patients 
w.ith end-stage, non-cancerous liver disease. 
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